TCW Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-14,882
| Closed | -$1.12M | – | 340 |
|
|
2021
Q1 | $1.12M | Sell |
14,882
-671,133
| -98% | -$54.8M | 0.01% | 285 |
|
|
2020
Q4 | $60.2M | Buy |
686,015
+1,934
| +0.3% | +$153K | 0.52% | 44 |
|
|
2020
Q3 | $52M | Sell |
684,081
-13,621
| -2% | -$1.38M | 0.57% | 45 |
|
|
2020
Q2 | $86.1M | Sell |
697,702
-40,675
| -6% | -$4.04M | 1% | 27 |
|
|
2020
Q1 | $62.4M | Sell |
738,377
-2,467
| -0.3% | -$213K | 0.86% | 34 |
|
|
2019
Q4 | $62.6M | Sell |
740,844
-32,064
| -4% | -$2.42M | 0.69% | 46 |
|
|
2019
Q3 | $52.1M | Sell |
772,908
-5,823
| -0.7% | -$449K | 0.59% | 56 |
|
|
2019
Q2 | $66.7M | Sell |
778,731
-9,003
| -1% | -$770K | 0.71% | 51 |
|
|
2019
Q1 | $70M | Sell |
787,734
-2,457
| -0.3% | -$228K | 0.67% | 59 |
|
|
2018
Q4 | $67.3M | Sell |
790,191
-68,536
| -8% | -$6.52M | 0.7% | 57 |
|
|
2018
Q3 | $83.3M | Sell |
858,727
-3,976
| -0.5% | -$397K | 0.68% | 56 |
|
|
2018
Q2 | $81.3M | Sell |
862,703
-46,268
| -5% | -$4.05M | 0.66% | 60 |
|
|
2018
Q1 | $73.7M | Sell |
908,971
-92,793
| -9% | -$7.96M | 0.6% | 64 |
|
|
2017
Q4 | $89.3M | Sell |
1,001,764
-71,205
| -7% | -$6.19M | 0.72% | 57 |
|
|
2017
Q3 | $99.9M | Buy |
1,072,969
+179,879
| +20% | +$15.9M | 0.79% | 50 |
|
|
2017
Q2 | $81.1M | Sell |
893,090
-18,682
| -2% | -$1.7M | 0.67% | 58 |
|
|
2017
Q1 | $80M | Sell |
911,772
-181,402
| -17% | -$16.1M | 0.67% | 62 |
|
|
2016
Q4 | $90.6M | Sell |
1,093,174
-55,844
| -5% | -$4.8M | 0.68% | 55 |
|
|
2016
Q3 | $106M | Sell |
1,149,018
-51,400
| -4% | -$4.84M | 0.81% | 52 |
|
|
2016
Q2 | $93.4M | Buy |
1,200,418
+22,028
| +2% | +$1.87M | 0.71% | 59 |
|
|
2016
Q1 | $97.2M | Sell |
1,178,390
-14,908
| -1% | -$1.21M | 0.71% | 60 |
|
|
2015
Q4 | $125M | Buy |
1,193,298
+228,796
| +24% | +$23.9M | 0.9% | 44 |
|
|
2015
Q3 | $102M | Sell |
964,502
-114,330
| -11% | -$15.3M | 0.73% | 53 |
|
|
2015
Q2 | $148M | Sell |
1,078,832
-474,423
| -31% | -$58.8M | 0.95% | 36 |
|
|
2015
Q1 | $194M | Sell |
1,553,255
-905,123
| -37% | -$95.9M | 0.93% | 30 |
|
|
2014
Q4 | $222M | Buy |
2,458,378
+230,350
| +10% | +$19.2M | 0.93% | 35 |
|
|
2014
Q3 | $161M | Buy |
2,228,028
+75,384
| +4% | +$4.95M | 0.65% | 48 |
|
|
2014
Q2 | $134M | Sell |
2,152,644
-212,597
| -9% | -$12.8M | 0.55% | 60 |
|
|
2014
Q1 | $161M | Sell |
2,365,241
-46,089
| -2% | -$3.4M | 0.67% | 46 |
|
|
2013
Q4 | $169M | Sell |
2,411,330
-23,443
| -1% | -$1.59M | 0.71% | 44 |
|
|
2013
Q3 | $176M | Buy |
2,434,773
+137,156
| +6% | +$9.12M | 0.81% | 37 |
|
|
2013
Q2 | $128M | Buy |
+2,297,617
| New | +$143M | 0.63% | 48 |
|
Other funds holding BMRN
BBA
TCW Group's BMRN Position: Q2 2021 in Review
TCW Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 14,882 shares — an estimated $1.12M sold.
TCW Group first reported a position in BMRN in Q2 2013 and held it in 32 quarters. The position peaked at $222M in Q4 2014. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.
- TCW Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
- TCW Group sold 14,882 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $1.12M.
- TCW Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 32 quarters.
- TCW Group's BioMarin Pharmaceuticals position peaked at $222M in Q4 2014.
- 529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.
Based on TCW Group's 13F filing for Q2 2021, filed 23 Jul 2021.